Last reviewed · How we verify
NCT04306406: RASPBERRY
Molecular Mechanisms of Raspberries Effect on Insulin Resistance and Inflammation
NA trial testing Raspberries in Inflammation in 9 participants. Completed in 13 January 2017.
13 January 2017
Quick facts
| Lead sponsor | Pennington Biomedical Research Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 9 |
| Start date | 7 January 2015 |
| Primary completion | 13 January 2017 |
| Estimated completion | 13 January 2017 |
Drugs / interventions tested
- Raspberries
Conditions studied
- Inflammation — all drugs for Inflammation →
- Insulin Resistance — all drugs for Insulin Resistance →
Sponsor
Pennington Biomedical Research Center — full company profile →
Who can join
Adults 18 to 70, any sex, with Inflammation or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Red raspberries (Rubus idaeus) are a good source of health enhancing hydrolyzable and condensed tannins, flavonoids, anthocyanins, phenolic acids, rheosmin, potassium, carotenoids, vitamin C, and vitamin K1. Compared to other berries commonly consumed in the US, the health benefits of red raspberries to improve pre-diabetes mellitus (PDM) and type 2 diabetes have never been explored. The clinical study proposed in this project seeks to investigate the protective effect of whole red raspberries against insulin resistance, oxidative stress, and inflammation in PDM and type 2 diabetic patients. The in vitro study proposed in the project will assist in identifying the molecular mechanisms by which whole red raspberry protect islet cells against oxidative stress, insulin resistance and loss of cell function.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bioactivity and mechanisms of flavonoids in decreasing insulin resistance.
Zhou M, Konigsberg WH, Hao C, Pan Y, et al · · 2023 · cited 21× · PMID 37036026 · DOI 10.1080/14756366.2023.2199168 -
Evidence-Based Anti-Diabetic Properties of Plant from the Occitan Valleys of the Piedmont Alps.
Boscaro V, Rivoira M, Sgorbini B, Bordano V, et al · · 2022 · cited 4× · PMID 36365189 · DOI 10.3390/pharmaceutics14112371
Verify or expand the search:
- PubMed search for NCT04306406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammation
Currently open trials in the same condition.
- NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
- NCT07479940 — Obesity and Aging: Impacts of Nutritional Counseling and Physical Exercise on Telomeres and Senescence Parameters · NA · active not recruiting
- NCT07269847 — Comparing a Healthy Beef-Centric Diet to a Healthy U.S.-Style Diet on Metabolic Health Outcomes in Pre-Diabetic Adults · NA · recruiting
- NCT07171450 — Cognitive Remediation · NA · recruiting
- NCT07411612 — The Association Between Postoperative Inflammatory and Neurological Serum Biomarker Concentrations and Occurrence of Pos · recruiting
Other Pennington Biomedical Research Center trials
Trials by the same sponsor.
- NCT07530718 — Body Composition Outcomes in MS Patients · not yet recruiting
- NCT07095972 — Continuous Glucose Monitoring in Metabolic Surgery · NA · not yet recruiting
- NCT07139821 — Dietary Iron Requirements · recruiting
- NCT07318064 — Ultra-processed Food Consumption and Health Pilot Study · NA · not yet recruiting
- NCT07305753 — CanCan Body Composition Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04306406 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pennington Biomedical Research Center
- Last refreshed: 12 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04306406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing